When it comes to cell, gene therapy, manufacturing is ‘Question one, two and three’
Panelists discussed the outlook for cell and gene therapy investing at the Alliance for Regenerative Medicine’s Cell & Gene Therapy Investor Day in New York Thursday. As cell and gene therapy become a focal point of investment in the public markets and private equity alike, one of the biggest barriers to them is still manufacturing.